Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes

Mitochondrial dysfunction is a pathological mediator of diabetic kidney disease (DKD). Our objective was to test the mitochondrially targeted agent, MitoQ, alone and in combination with first line therapy for DKD. Intervention therapies (i) vehicle (D); (ii) MitoQ (DMitoQ;0.6 mg/kg/day); (iii) Ramip...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Micheal S., Flemming, Nicole B., Gallo, Linda A., Fotheringham, Amelia K., McCarthy, Domenica A., Zhuang, Aowen, Tang, Peter H., Borg, Danielle J., Shaw, Hannah, Harvie, Benjamin, Briskey, David R., Roberts, Llion A., Plan, Manuel R., Murphy, Michael P., Hodson, Mark P., Forbes, Josephine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680236/
https://www.ncbi.nlm.nih.gov/pubmed/29123192
http://dx.doi.org/10.1038/s41598-017-15589-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680236/
https://www.ncbi.nlm.nih.gov/pubmed/29123192
http://dx.doi.org/10.1038/s41598-017-15589-x

Ejemplares similares